Clinical Research Directory

Nitrous Oxide as Treatment for Fibromyalgia

The purpose of this study is to explore a potential role of nitrous oxide in treating pain associated with fibromyalgia.

Treating Central Neuropathic Pain With Low Dose Naltrexone for People With Spinal Cord Injury

The goal of this pilot clinical trial is to find out how well low dose naltrexone works for people with pain due to spinal cord injury. The main questions it aims to answer are: will low dose naltrexone reduce pain, and increase the quality of life for people with central neuropathic pain due to spinal cord injury. Hypothesis 1: LDN will decrease the severity of CNP in adult patients with SCI as measured by the Neuropathic Pain Scale (NPS) Hypothesis 2: LDN will improve quality of life of patients with SCI as measured by various validated clinical tools There is no comparison group. This study is being completed to give investigators more information for how to best run a larger clinical trial. Participants will be asked to take an oral dose of 4.5mg of naltrexone, daily, for 12 weeks.

Low Intensity Focused Ultrasound Modulation of Thalamic Nuclei for Central Neuropathic Pain.

LIFUP may have a modulatory effect on neuronal circuitry involved in pain, specifically when applied to the anterior thalamic nuclei, which is an important part of the pain circuit .Precise laboratory studies will reveal the indications under which LIFUP produces analgesia. The first step in evaluating LIFUP as a therapy for pain control is to determine whether LIFUP produces analgesia through suppression of the anterior thalamus. The primary objective is to evaluate the short-term analgesic effects of thalamic analgesia caused by LIFUP through: 1. Quantitative sensory testing (QST) and conditioned pain modulation testing (CPM) that allow the assessment of perceptual responses to quantifiable sensory stimuli, evaluated to characterize somatosensory function or dysfunction. 2. Short-form McGill Pain Questionnaire; 3. Brief Inventory Form, which includes pain severity index (average of questions 3-6) and pain interference with daily activities (average of questions 9A-9G, ranging from 0 to 70, where 70 indicates maximum possible pain interference); 4. Douleur Neuropathique-4 to assess neuropathic pain, being positive for scores ≥4; 5. Neuropathic Pain Symptom Inventory (NPSI), which provides characterization of neuropathic pain symptoms in 5 domains (superficial and deep) spontaneous pain, paroxysmal pain, evoked pain and paresthesia. In association, analysis of its responses with others qualitative scales will be made described above: 1. Hamilton D + A 2. Medication use (Brief Pain Inventory) 3. Interference with daily activities (Brief Pain Inventory, quantified by Medication Quantification Scale) 4. Cognition - Montreal Cognitive Assessment (Mo CA)5 Adverse events 5. Blinding assessment 6. Variation in Global Impression of Change (CGI)

Machine-Learning Based EEG Biomarkers for Personalized Interventions

The goal of this observational study is to develop a machine learning model to predict the outcome of a transcranial direct current stimulation (tDCS) treatment in patients suffering from neuropathic pain derived from a spinal cord injury. The main question it aims to answer is: • Can electroencephalography (EEG) and clinical assessment data predict the success of tDCS treatment in neuropathic pain patients? Participants will: * Undergo EEG recording sessions to collect brain activity data before treatment. * Complete clinical assessments, including medical diagnostics and questionnaires focused on factors related to neuropathic pain before and after treatment.

Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China

To evaluate the efficacy and safety of HSK16149 capsule in the treatment of moderate to severe central neuropathic pain compared with placebo.